Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
Ridgefield
Connecticut
06877
United States
Tel: 203-798-9988
Website: http://us.boehringer-ingelheim.com/
227 articles about Boehringer Ingelheim Pharmaceuticals, Inc.
-
BioMed X and Boehringer Ingelheim Start New Joint Research Group in Bacterial Modulation of Innate Immunity
11/27/2017
The focus of the group will be to identify novel regulatory pathways within the innate immune system, through understanding molecular mechanisms employed by bacteria to evade or modulate innate immunity.
-
Boehringer Ingelheim Makes Many of Its Best Molecules Openly Available to the Scientific Community Via opnMe.com to Unlock Their Full Potential
11/20/2017
The platform offers direct access to molecules for independent research as well as other molecules for partnering with Boehringer Ingelheim.
-
Boehringer Ingelheim's New RE-VERSE AD Analyses Provide Additional Insights on Impact of Idarucizumab (Praxbind) in Pradaxa Patients With GI Bleeding or Needing Emergency Surgery
11/14/2017
The analyses provide further insights on the use of idarucizumab in patients with GI bleeding and in those with a need for urgent surgery or intervention.
-
Boehringer Ingelheim Release: Jardiance Reduced Risk of Cardiovascular Death in Adults With Type 2 Diabetes and Peripheral Artery Disease
11/14/2017
hese results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly at the AHA Scientific Sessions 2017 in Anaheim, Calif. and simultaneously published online in the AHA's journal, Circulation.
-
Results From Boehringer Ingelheim's Six-Month Lung Imaging Study Showed Slowing of Fibrotic Progression in Patients With IPF Treated With Ofev Versus Placebo
11/10/2017
The results are being presented at the PFF Summit 2017, November 9-11 in Nashville, Tenn.
-
CellSight Technologies Announces Strategic Collaboration With Boehringer Ingelheim to Develop a New Technology for Monitoring Anti-Tumor T-Cell Activation
11/8/2017
The focus of the trial is to determine if early PET scans, at 6-12 weeks after the initial anti-PD1 inhibitor therapy dose, with the VisAcT tracer are predictive of response to immunotherapy.
-
Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.
-
Boehringer Ingelheim's Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo
11/7/2017
The 48-week data showed that Cyltezo is equivalent, with no clinically meaningful differences in efficacy, safety and immunogenicity to Humira in people with moderately-to-severely active RA, including in patients who switched from Humira to Cyltezo at week 24.
-
Boehringer Ingelheim Release: Efficacy and Safety Maintained in Patients Who Switched From Humira to Biosimilar Cyltezo
11/6/2017
Boehringer Ingelheim today announced one-year data from VOLTAIRE-RA, a pivotal Phase III clinical trial comparing Cyltezo and reference product Humira.
-
Boehringer Ingelheim Expands Collaboration With Sarah Cannon Research Institute to Investigate Novel Immuno-Oncology Combination Therapy
10/30/2017
Boehringer Ingelheim and Sarah Cannon Research Institute today announced an expansion of their strategic partnership which combines Boehringer Ingelheim's oncology research and Sarah Cannon's expertise in clinical trial design.
-
Boehringer Ingelheim Release: Ofev Demonstrates Consistent Long-Term Efficacy in IPF Regardless of Baseline Lung Function
10/23/2017
Boehringer Ingelheim announced today the presentation of a new analysis on the use of Ofev (nintedanib) in treating people with idiopathic pulmonary fibrosis (IPF) at the 2017 CHEST Annual Meeting.
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Results from The INJOURNEY Trial Investigating Ofev With Add-On Pirfenidone Provide New Insights Into This Combination Treatment For IPF
9/11/2017
-
Boehringer Ingelheim Pharmaceuticals, Inc. Receives FDA Approval For Cyltezo (Adalimumab-Adbm), A Biosimilar To Humira, For The Treatment Of Multiple Chronic Inflammatory Diseases
8/29/2017
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Support Program Provides Free Medicine And Resources For People Living With COPD Prescribed STIOLTO RESPIMAT (Tiotropium Bromide And Olodaterol) Inhalation Spray
10/12/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Of INPULSIS Trials Demonstrates Efficacy Of OFEV (Nintedanib) Across A Range Of IPF Patients Using Broader Diagnostic Criteria
6/27/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: : Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) In Emergency Situations
4/4/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Analysis Confirms OFEV (nintedanib) Slows Disease Progression In IPF And Reduces Risk Of Acute Exacerbations
2/25/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Country Music Artist Joe Nichols Raises Awareness of Rare Lung Disease That Claimed His Father's Life and Leaves Those Affected "Breathless"
2/18/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range Of Measures
2/9/2016
-
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Published Data Show STIOLTO RESPIMAT Provides Clinically Meaningful Improvements In COPD Health-Related Quality Of Life Measure
8/18/2015